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Abstract
Objective—To measure the effects of a five-minute delay (DCC) versus immediate cord 
clamping (ICC) on residual placental blood volume (RPBV) at birth, and hemoglobin and serum 
bilirubin at 24 to 48 hours of age.
Study Design—In this prospective randomized controlled trial, seventy-three women with term 
(37 to 41 weeks) singleton fetuses were randomized to DCC (≥5 minutes; n=37) or ICC (<20 
seconds; n=36).
Results—Maternal and infant demographics were not different between groups. Mean cord 
clamping time was 303 ± 121 (DCC) versus 23 ± 59 (ICC) seconds (p<0.001) with 10 protocol 
violations. Cord milking was the proxy for DCC (n = 11) when the provider could not wait. Infants 
randomized to DCC compared to ICC had significantly less RPBV (20.0 vs 30.8 mL/kg, p<0.001), 
higher hemoglobin levels (19.4 vs 17.8 g/dL, p=0.002) at 24 to 48 hours, with no difference in 
bilirubin levels.
Conclusions—Term infants had early hematological advantage of DCC without increases in 
hyperbilirubinemia or symptomatic polycythemia.
Keywords
delayed cord clamping; umbilical cord milking; hemoglobin; bilirubin; residual placental blood 
volume; placental transfusion
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Introduction
At each birth, obstetrical providers decide when to clamp and cut the umbilical cord. 
Immediate cord clamping (ICC) has become the routine practice in the United States without 
scientific evaluation of its potential impact on an infant’s health and development. Clear 
evidence to guide a provider’s decision for term infants is not sufficient at this time.1 Fear of 
hyperbilirubinemia and polycythemia are concerns that have hindered the adoption of 
delayed cord clamping (DCC) as routine care.
The amount of blood an infant obtains with placental transfusion is considerable. When cord 
clamping is delayed at birth or the umbilical cord is milked, infants obtain a placental 
transfusion resulting in approximately a 20 to 30% increase in blood volume and a 50% 
increase in red cell volume.2, 3 Although changes in practice are beginning to favor DCC, 
evidence of long-term outcomes is limited.
Older physiologic studies on placental transfusion or DCC show advantages for term infants 
that include increased red cell volume and higher hematocrit levels 4, 5, 6; improved 
cutaneous perfusion and higher skin temperature 7, 8; increased renal blood flow with higher 
urine output and less sodium loss 9; and an increased red blood cell flow to the brain and 
gut.10 None of these studies followed the infants beyond hospitalization. None reported 
complications or adverse events.
In the latest Cochrane review on term infants, McDonald et al (2013) found no significant 
differences between infants with ICC or DCC for most neonatal morbidities such as Apgar 
score less than seven at five minutes, admission to the neonatal intensive care unit, or 
clinical jaundice.11 However, in the DCC group, mean birthweight (mean increase of 101 
grams) and hemoglobin concentrations in infants at 24 to 48 hours were significantly higher. 
While there was no difference in the diagnosis of clinical jaundice, 2% fewer infants in the 
ICC group required phototherapy compared to the DCC group. Improvement in iron stores 
appeared to persist into infancy. Infants receiving ICC were twice as likely to be iron 
deficient at three to six months compared with infants receiving DCC (RR 2.65, 95% CI 
1.04 to 6.73).
We have conducted two pilot randomized controlled trials involving full-term infants. The 
first (n = 24) demonstrated that milking the umbilical cord (UCM) five times after cesarean 
section, in contrast to ICC, resulted in significantly higher hemoglobin and hematocrit levels 
at 24–48 hours and less residual placental blood volume (RPBV) with no reports of adverse 
neonatal events.12 The second pilot study compared RPBV for infants (n=36) placed on the 
maternal abdomen and assigned to one of four groups: ICC, a delay of two minutes, a delay 
of five minutes, or UCM. Infants placed on the maternal abdomen immediately after birth 
who were assigned to a five-minute delay in cord clamping time received a significantly 
larger placental transfusion than those with a two-minute delay.13 The results of these two 
pilot feasibility studies formed the basis for our current study design.
Our current randomized trial tests the effects of DCC for five minutes with term infants 
placed skin-to-skin on the maternal abdomen with the aim of assessing brain myelin 
deposition and developmental outcomes at four months, twelve months and two years of age 
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(NCT01620008). This paper reports on the birth data, clinical safety issues, and the two-day 
hospital outcomes for the cohort of infants and mothers. We predicted that DCC would 
result in less RPBV, higher hematocrit and hemoglobin at 48 hours of age, and no 
differences in hyperbilirubinemia or polycythemia.
Materials and Methods
Enrollment for this prospective randomized controlled trial was conducted from July 2013 to 
November 2015 at Women and Infants Hospital (WIH) in Providence, Rhode Island after 
approval by the WIH and the University of Rhode Island Institutional Review Boards. 
Follow-up for this study is out to 24 months of age and will be finished in November 2017. 
An independent data safety and monitoring committee reviewed the data after 42 infants 
were randomly assigned. No concerns were identified.
Pregnant women were recruited from the WIH obstetric clinic, private obstetric offices, WIH 
childbirth and breastfeeding classes, at community affairs and brochures placed in obstetric 
and pediatric offices. Women were eligible if they were expecting a healthy singleton 
pregnancy in the vertex position at term (37–416/7 weeks), had no evidence of medical or 
obstetrical complications (i.e. hypertension, pre-eclampsia, diabetes, smoking, substance 
abuse, suspected intrauterine growth restriction), were planning on breastfeeding, spoke 
English, and were at least 18 years of age. Infants with evidence of intrauterine growth 
restriction and serious congenital anomalies were excluded. All participants were screened 
and informed about the study by registered nurses (RNs) who completed the written 
informed consent with each mother. Doulas were assigned as research assistants (RAs) to 
each woman to support communication both pre-labor and postpartum and to attend the 
births, assign randomization, collect the RPBV, conduct two-day hospital visits, and assist 
with follow-up.
A statistician not involved in the trial established the randomization plan before the study 
began. Blocked, stratified randomization of subjects by gender (or unknown gender) was 
used to assign the groups with a pre-specified equal probability. Sequenced and sealed 
envelopes identifying the stratification and group assignment on cards were prepared and 
kept in a secured area on the Labor and Delivery Unit. The study RAs randomized mothers 
based on the next study card designation when women went into active labor.
At the time of birth, infants were randomized to either ICC (the control group) or DCC (the 
intervention group). The provider placed the infant skin-to-skin on the maternal abdomen 
immediately at birth where they were dried and stayed for at least 30 minutes. Those 
randomized to ICC received the hospital’s usual practice of cord clamping (≤20 seconds). 
For infants receiving DCC, the RAs used a stopwatch to notify the provider to clamp at five 
minutes. If unable to carry out the DCC protocol, or if delivery was by cesarean section, the 
cord was milked five times before being clamped (n=11).
The RPBV was collected via a blood collection bag and weighed (1 gm = 1mL). The 
provider inserted the blood bag needle into the umbilical vein when collection was in-utero. 
Ex-utero collection was done by suspending the placenta and draining into blood bag via 
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needle inserted in the vein. The cord was drained until there was no more blood returned 
usually about one to two minutes. Blood was collected with the placenta in-utero at vaginal 
deliveries (n = 54) and ex-utero after cesarean section (n = 19) by necessity. Cord blood 
samples were collected for hemoglobin, hematocrit, ferritin, total serum bilirubin (TSB), and 
C-reactive protein (CRP) either by the obstetrical provider or the RAs. At 24–48 hours, 
when the state recommended newborn metabolic screening sample was drawn, laboratory 
personnel drew a capillary sample from the infant’s heel for hemoglobin, hematocrit, and 
TSB. All subsequent nursery care was routine.
Outcome variables for the neonatal data were RPBV at birth, hematocrit, hemoglobin, and 
TSB levels at 24 to 48 hours, hyperbilirubinemia, symptomatic polycythemia, anemia at 24 
to 48 hours, and admission to the NICU. RPBV was defined as the amount of blood (mL/kg 
of birth weight) obtained from the umbilical cord by drainage into a blood bag (Blood-Pack 
Unit, Fenwal Inc., Lake Zurich, IL, USA) after birth with the placenta either in-utero 
(vaginal delivery) or ex-utero (cesarean section). Hematocrit and hemoglobin were 
peripheral capillary samples and analyzed in the WIH laboratory (Coulter LH750 
Hematology Analyzer, Beckman-Coulter, Miami, FL, USA). Risk of hyperbilirubinemia was 
assessed by plotting the TSB levels by age (in hours) [birth and 24–48 hour samples] on the 
Bhutani Nomogram.14 This allowed us to quantify hyperbilirubinemia risk and compare 
TSB levels between groups. We analyzed the peak level each infant reached at any time 
during hospitalization (range 31–56 hours of age). Symptomatic polycythemia was defined 
as hematocrit over 65% with evidence of newborn distress as assessed by the pediatric 
providers.15, 16 Anemia was defined as capillary hematocrit below 47%.17
The intervention could not be masked because of the obvious nature of cord clamping. Staff 
who attended each birth were asked not to reveal the infant’s randomization group in the 
medical record. Laboratory and nursery personnel were masked to the randomization group 
and results of the 24–48 hour blood work. Research staff collecting on-going clinical data 
and follow-up data remained blinded to the infants’ randomization.
Power analyses for RPBV and two day hematocrit and hemoglobin require less than 15 
infants in each group. Consequently we based our sample size on the study’s four-month 
outcome variable, ferritin level (μg/L), for the continuing longitudinal study. Data from prior 
studies suggest that without adjustment sample sizes of 30 subjects per group would have 
more than 80% power at alpha of 0.05 to detect a 20% difference in ferritin levels between 
the two treatment arms.18, 19, 20
Data analyses included two-sided Pearson’s chi-square tests, t-tests, and Wilcoxon rank-sum 
tests for non-normally distributed variables. Odds ratios and 95% confidence intervals were 
examined as appropriate. Primary analyses were conducted using intention-to-treat, and 
sensitivity analyses were conducted using actual treatment in order to assess the robustness 
of the findings and to examine results of the biologic variables.
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Results
Seventy-three pregnant women and their fetuses between 37 and 416/7 weeks gestation were 
randomized at birth from July 2013 through November 2015 (Figure 1). Thirty six infants 
were randomized to the ICC group and 37 to the DCC group.
Table 1 shows that there were no significant differences between the DCC and ICC groups 
with respect to maternal demographics or clinical variables. Table 2 shows no significant 
differences between the two groups on the neonatal demographics and clinical variables 
except for cord clamping time and RPBV. Per protocol, cord-clamping time was 
significantly longer in the DCC group. Cord clamping time including and excluding those 
infants who received UCM is noted to assess compliance with the protocol. As expected, 
RPBV was less in those infants who received DCC or UCM (mean difference of 10.8 mL/
kg). Infants delivered by cesarean section had less RPBV than infants born vaginally but this 
did not reach a level of significance. There were 10 protocol violations. Reasons included 1) 
the clinical situation of meconium or shoulder dystocia (n=4), 2) the provider preference for 
the DCC or UCM group (n=2), 3) a misunderstanding between RAs and provider (n=2), and 
4) parental request at time of delivery (n=2).
Table 3 shows blood values at approximately 24 to 48 hours of age as well as the incidence 
of jaundice and polycythemia comparing groups by intention to treat and actual treatment. 
As expected, there were significant differences in hemoglobin and hematocrit levels without 
differences in peak TSB levels or symptomatic polycythemia between groups. None of the 
six infants in the DCC group with hematocrit levels > 65% exhibited symptoms or received 
any treatment for polycythemia. Two infants were admitted to the NICU briefly (DCC = 1; 
ICC = 1) for observation for respiratory distress (DCC) and on day two for hypoglycemia 
(ICC). Two infants (ICC) were readmitted for hyperbilirubinemia: one on day three for a 
bilirubin level of 17.3 mg/dL and the other on day 12 for “likely” breast milk jaundice. Five 
infants (14%) in the ICC group had a two-day hematocrit level < 47% but none of the infants 
were diagnosed with anemia by pediatric providers.
While analysis by intention-to-treat showed significantly more infants in the DCC group 
needing phototherapy, analysis by actual treatment revealed that there were two infants in 
each group who received phototherapy during hospital stay. Treatment was provided at the 
discretion of the managing pediatrician.
All study recruitment was completed during the prenatal period (late second and early third 
trimester). We did not have access to the data of women who refused enrollment or who 
were not enrolled.
Discussion
This is the first study of DCC to be conducted in the United States on healthy term infants 
and the first in North America since 1980.21 It is also the most recent study to use a five-
minute delay with infants placed skin-to-skin on the maternal abdomen. In 2012, the ACOG 
statement on DCC offered a consensus that evidence was lacking to recommend DCC or 
UCM for term infants. This current study is designed to examine short-term and long-term 
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outcomes over a two-year span. In this report, we have shown that term infants with DCC of 
five minutes (or UCM x 5) have lower amounts of RPBV associated with higher hematocrit 
and hemoglobin at 24 to 48 hours and no increase in jaundice, symptomatic polycythemia, 
or other adverse effects.
Our use of a five-minute delay along with placement on the maternal abdomen is unique 
among current cord clamping studies. Our pilot data showed that placing the term infant on 
the maternal abdomen during a delay in cord clamping slows the transfer of placental blood 
necessitating a five-minute delay to obtain a full placental transfusion.13 Others have shown 
no difference in weight from immediately after birth to after clamping at 2 minutes with the 
infants placed either on the maternal abdomen or at the introitus.22 However, the overall 
weight gain by the infants in Vain’s study was 52 to 59 grams – slightly more than half of 
the weight gain predicted by the meta-analysis.11 This reinforces our position that a two 
minute delay is not long enough for a full placental transfusion when the infant is placed on 
the maternal abdomen. We attempted to obtain the largest placental transfusion possible to 
maximize blood volume for comparisons of long-term infant outcomes with ICC versus 
DCC.
There is currently no ethical way to measure blood volume of healthy term infants thus 
necessitating the use of measures of inference such as two-day hematocrit and hemoglobin 
and RPBV. Measurement of the RPBV can be used to approximate the amount of blood 
transfused to the infant during the first few minutes after birth. While documentation of 
RPBV is not essential in studies of DCC, we included this measure to suggest mechanisms 
of action if our longitudinal study data should show DCC to be an advantage. Our findings 
are consistent with a previous study that measured RPBV by drainage following vaginal 
birth 4, 23 and with a study showing more transfer of placental blood to the infant with DCC 
via weighing infants with attached cord over the first five minutes after birth.3 Recent studies 
of cord blood harvesting report higher total volume of blood and stem cell yields with in-
utero rather than ex-utero collection.24, 25 We used ex-utero collection at cesarean section to 
get better drainage and allow the surgeon to close the uterus and a few times at vaginal birth 
when the placenta delivered quickly.
There is a widespread belief that placental transfusion (DCC/UCM) increases an infant's risk 
for jaundice or polycythemia. This has hindered the adoption of placental transfusion 
techniques in clinical practice.26 The most recent Cochrane review on term infants reports 
no increase in clinical jaundice although they report a 2% increase of infants needing 
phototherapy.11 Bilirubin is a known antioxidant. Zahir and colleagues (2015) suggest that 
bilirubin levels that are elevated but still within a normal range (associated with normal 
physiologic jaundice) may provide a unique protective antioxidant effect, especially for the 
developing brain.27 None of the published RCTs on term infants have demonstrated an 
increase in jaundice 11, 20, 28, 29 and experts refute that DCC causes hyperbilirubinemia (A. 
McDonagh, personal communication, 2014). We used the Bhutani Nomogram for 
designation of hyperbilirubinemia risk to define hyperbilirubinemia in our subjects.14 This 
allowed a quantification of levels of risk and a comparison of the two groups of infants.14 
We included results by sensitivity analyses to show the actual effect of DCC on 
hyperbilirubinemia rather than the effect of being assigned to receive DCC. Intention-to-treat 
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analyses show the compliance with the protocol. Analyses by actual treatment are needed to 
assess and clarify differences in biologic variables affected by the protocol. Experts suggest 
hemolytic disorders (i.e. ABO incompatibility) and genetic predisposition (i.e. G6PD) are 
most frequently the cause for severe hyperbilirubinemia.30, 31 Even in infants with red cell 
alloimmunization who required in utero transfusion, Garabedian et al (2016) found that 
DCC at birth resulted in improved hemoglobin levels at birth, less need for postnatal 
exchange transfusions, and no increase in severe hyperbilirubinemia.32 Thus, evidence that 
the practice of DCC is associated with severe hyperbilirubinemia is lacking.
We defined polycythemia as a hematocrit >65% using capillary samples. We used capillary 
samples to avoid collecting venous blood on two-day old healthy term infants. Only one 
study infant had a venous blood draw for a capillary hematocrit value of 61.5%. The infant 
did not have polycythemia. Oh and Lind (1966) reported venous samples to be 6 to 9 
percentage points lower than capillary samples in infants with DCC.5 Thus our results likely 
err on the side of caution. No infant with a capillary hematocrit > 65% exhibited symptoms. 
The one infant who had a capillary hematocrit level >70% had a gentle easy birth, breastfed 
very well and remained asymptomatic. Hemoglobin and hematocrit are not routinely 
collected on all normal newborns at WIH therefore we felt it was ethical to mask nursery 
personnel to our laboratory findings.33 Blood hyperviscosity secondary to polycythemia 
(hematocrit > 65%) is frequently cited as a reason for providers to clamp and cut the cord 
immediately as a way to prevent over transfusion of red blood cells at the time of birth. 
Christensen and colleagues (2014) demonstrated that placental transfusion will not lead to 
neonatal hyperviscosity.34
Lack of equipoise in the community was an important factor that made enrollment difficult. 
There is a large amount of available information on the Internet extolling the benefits of 
DCC. Many women we approached did not want to be randomized. We revised our study 
plans to include a parallel "preference" group. The intention was to balance women who 
preferred DCC and women who preferred ICC for cord blood banking/harvesting. Early in 
the study, the local cord blood collection bank closed for financial reasons. As a result only 
one woman requested ICC so the balanced “preference” plan was unsuccessful. Although 
there were no differences in biologic variables between the randomized group (n = 73) and 
the preference group (n =33), the women in our preference group had significantly higher 
socio-economic status than our randomized group. Although data from our preference group 
are not analyzed in this paper, we plan to evaluate whether inclusion of those infants is 
appropriate when longitudinal data are examined over the two-year follow-up period. The 
follow-up assessments are ongoing until November 2017.
Term infants who were randomized to DCC left less residual blood volume behind in the 
placenta. The DCC infants had higher neonatal hemoglobin and hematocrit levels at 24 to 48 
hours of age with no differences on peak TSB levels at 24 to 48 hours. There were no 
indicators of differences between groups in incidence of hyperbilirubinemia or symptomatic 
polycythemia. The study results support the early hematological advantage of DCC while 
demonstrating no association with an increase in hyperbilirubinemia or symptomatic 
polycythemia out to 48 hours of age.
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Figure 1. 
Flow Chart
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Table 1
Maternal Demographics and Clinical Variables at Birth (ITT)
Maternal Characteristics DCC (n=37) ICC (n=36) P value
Age (years) 28.3 ± 5.5 27.2 ± 5 0.35
Primipara 15 (41) 14 (39) 0.89
Maternal education (years) 14 ± 2.7 14 ± 2.6 0.96
Insurance, public 23 (62) 21 (58) 0.74
Hemoglobin at admission (g/dL) 11.6 ± 1 12.0 ± 1 0.14
Lead level at admission (mcg/dL) 1.0 ± 0.4 1.1 ± 0.4 0.76
Ferritin at admission (ng/mL) 23.4 ± 22 16.9 ± 14 0.07
Mode of delivery
 Spontaneous vaginal 27 (73) 25 (69) 0.28
 Instrumented vaginal 2 (5) 0 (0)
 Cesarean section 8 (22) 11 (31)
N (%) or mean ± SD
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Table 2
Infant Demographics and Clinical Variables at Birth (ITT)
Infant Characteristics DCC (n=37) ICC (n=36) P value
Gestational Age, weeks 39.5 ± 1 (37–41) 39.4 ± 1 (37–41) 0.54
Male: Female 19:18 18:18 0.91
Cord Clamping Time (sec) (includes UCM) Range 192 ± 171 (5–647) 23.1 ± 59 (3–360) 0.001
Cord Clamping Time (sec) (without UCM) Range 303 ± 121 (55–647) 10 ± 6 (3–25) 0.001
Apgar Scores 1 minute, median (range)
 5 minutes
8 (2–9)
9 (8–10)
8 (2–9)
9 (5–9)
0.65
0.24
Apgar score ≤7 at 5 min 0 (0) 1 (3) 0.31
Temperature <36.6°C in first 15 minutes 1 (3) 0 (0) 0.32
Birth Weight (g) Range 3584 ± 497 (2455–4410) 3433 ± 454 (2730–4630) 0.18
RPBV (mL/kg) Range 20.0 ± 8.5 (0–36.8) 30.8 ± 9.6 (14.1–65.2) 0.001
Cord blood Hemoglobin (g/dL) Range 14.8 ± 2 (12.0–19.9) 15.2 ± 2 (12–18.9) 0.29
Cord blood Hematocrit (%)Range 44.2 ± 6.3 (24.5–59.2) 45.9 ± 4.7 (36–53) 0.24
Cord blood Ferritin (ng/mL) Range 154.3 ± 115 (16.9–570.4) 134.6 ± 81 (18.1–365.1) 0.42
Protocol Deviations 5 (14) 5 (14) 0.96
Breastfeeding at time of discharge 18 (50) 19 (56) 0.62
N (%) or mean ± SD (range)
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